Thromb Haemost 2007; 97(04): 546-551
DOI: 10.1160/TH06-12-0743
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Mutational screening of six afibrinogenemic patients: Identification and characterization of four novel molecular defects

Luca Monaldini
1   Department of Biology and Genetics for Medical Sciences, University of Milan, Milan, Italy
,
Rosanna Asselta
1   Department of Biology and Genetics for Medical Sciences, University of Milan, Milan, Italy
,
Stefano Duga
1   Department of Biology and Genetics for Medical Sciences, University of Milan, Milan, Italy
,
Flora Peyvandi
2   Angelo Bianchi Bonomi – Fondazione Luigi Villa, Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Fondazione IRCCS, University of Milan, Milan, Italy
,
Mehran Karimi
3   Hemostasis and Thrombosis Unit, Hematology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
,
Massimo Malcovati
1   Department of Biology and Genetics for Medical Sciences, University of Milan, Milan, Italy
,
Maria Luisa Tenchini
1   Department of Biology and Genetics for Medical Sciences, University of Milan, Milan, Italy
› Author Affiliations
Financial support: The financial support of Telethon – Italy (Grant n. GGP030261) is gratefully acknowledged. This work was supported by PRIN (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale, Grant n. 2005058307_002).
Further Information

Publication History

Received 29 December 2006

Accepted after revision 08 February 2007

Publication Date:
24 November 2017 (online)

Summary

Congenital afibrinogenemia (CAF) is a rare coagulation disorder characterized by very low or unmeasurable levels of functional and immunoreactive fibrinogen in plasma, associated with a hemorrhagic phenotype of variable severity. It is transmitted as an autosomal recessive trait (prevalence 1:1,000,000) and is invariantly associated with mutations affecting one of the three fibrinogen genes (FGA, FGB, and FGG, coding for Aα, Bβ, and γ chain, respectively). Fibrinogen is secreted by hepatocytes as a hexamer composed of two copies of each chain; the lack of one chain has been demonstrated to prevent its secretion. Most genetic defects causing afibrinogenemia are point mutations, where- as only three large deletions have been identified so far, all affecting the FGA gene. We here report the molecular characterization of six unrelated afibrinogenemic patients leading to the identification of eight different mutations, four hitherto unknown: a 4.1-Kb large deletion involving exon 1 of FGA (AC107385:g. 65682_69828del), two nonsense mutations (p.Trp229X in FGA and p.Trp266X in FGB), and an ins-del mutation (g.1787_ 1789del3ins12) in FGA. The molecular characterization of CAFcausing genetic defects increases our understanding on the genetic basis of this disease and might be helpful for prenatal screening purposes, as also demonstrated during this study.

 
  • References

  • 1 Doolittle RF. Fibrinogen and fibrin. Annu Rev Biochem 1984; 53: 195-229.
  • 2 Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3: 1894-1904.
  • 3 Kent WJ, Sugnet CW, Furey TS. et al. The Human Genome Browser at UCSC. Genome Res 2002; 12: 996-1006. http://genome.ucsc.edu/. Accessed November 24th 2006;
  • 4 Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104: 1243-1252.
  • 5 Mosesson MW. Fibrinogen gamma chain functions. J Thromb Haemost 2003; 1: 231-238.
  • 6 Asselta R, Duga S, Tenchini ML. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 2006; 4: 2115-2129.
  • 7 Asselta R, Duga S, Spena S. et al. Congenital afibrinogenemia: mutations leading to premature termination codons in fibrinogen A α -chain gene are not associated with the decay of the mutant mRNAs. Blood 2001; 98: 3685-3692.
  • 8 Cattaneo M, Bettega D, Lombardi R. et al. Sustained correction of the bleeding time in an afibrinogenaemic patient after infusion of fresh frozen plasma. Br J Haematol 1992; 82: 388-390.
  • 9 Bakker E, Kneppers ALJ, Voorhoeve E. et al. Advances and pitfalls in prenatal diagnosis: Five year DNA-analysis for Duchenne and Becker muscular dystrophy and Hemophilia. In: Muscular dystrophy research from molecular diagnosis towards therapy. Amsterdam,. 1991: 67-76.
  • 10 Ausubel FM, Brent R, Kingston RE. et al. Current Protocols in Molecular Biology. NewYork: 2001. 1: chapter 1.2.1
  • 11 Sherry ST, Ward MH, Kholodov M. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29: 308-311.
  • 12 Monaldini L, Asselta R, Malcovati M. et al. The DNA-pooling technique allowed for the identification of three novel mutations responsible for afibrinogenemia. J Thromb Haemost 2005; 3: 2591-2593.
  • 13 den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000; 15: 7-12.
  • 14 Wells RD, Dere R, Hebert ML. et al. Advances in mechanisms of genetic instability related to hereditary neurological diseases. Nucleic Acid Res 2005; 33: 3785-3798.
  • 15 Spena S, Duga S, Asselta R. et al. Congenital afibrinogenaemia caused by uniparental isodisomy of chromosome 4 containing a novel 15-kb deletion involving fibrinogen Aalpha-chain gene. Eur J Hum Genet 2004; 12: 891-898.
  • 16 Neerman-Arbez M, Antonarakis SE, Honsberger A. et al. The 11 kb FGA deletion responsible for congenital afibrinogenaemia is mediated by a short direct repeat in the fibrinogen gene cluster. Eur J Hum Genet 1999; 7: 897-902.
  • 17 Labuda D, Zietkiwicz E, Mitchell GA. Alu elements as a source of genome variation: deleterious effects and evolutionary novelties. In: The impact of short interspersed elements (SINEs) on the host genome. Austin, Texas, USA, 1995; 1-24.
  • 18 Burwinkel B, Kilimann MW. Unequal homologous recombination between LINE-1 elements as a mutational mechanism in human genetic disease. J Mol Biol 1998; 277: 513-517.
  • 19 Watanabe K, Shibuya A, Ishii E. et al. Identification of simultaneous mutation of fibrinogen alpha chain and protein C genes in a Japanese kindred. Br J Haematol 2003; 120: 101-108.
  • 20 Vu D, Di Sanza C, Caille D. et al. Quality control of fibrinogen secretion in the molecular pathogenesis of congenital afibrinogenemia. Hum Mol Genet 2005; 14: 3271-3280.
  • 21 Asselta R, Spena S, Duga S. et al. Analysis of Iranian patients allowed the identification of the first truncating mutation in the fibrinogen Bbeta-chain gene causing afibrinogenemia. Haematologica 2002; 87: 855-859.
  • 22 Neerman-Arbez M, Vu D, Abu-Libdeh B. et al. Prenatal diagnosis for congenital afibrinogenemia caused by a novel nonsense mutation in the FGB gene in a Palestinian family. Blood 2003; 101: 3492-3494.